[1. Breitrose, PE. History (of the Stanford Prevention Research Center). [Online] Stanford Prevention Research Center. [Dátum: 1. FEB 2011.] http://prevention.stanford.edu/about/history.html.]Search in Google Scholar
[2. Chung, CP; Avalos, I; Oeser, A; Gebretsadik, T; Shintani, A; Raggi, P; Michael Stein, C. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007, 66, 208-214 pp.]Search in Google Scholar
[3. Chung, CP; Oeser, A; Solus, JF; Avalos, I; Gebretsadik, T; Shintani, A; Raggi, P; Sokka, T; Pincus, T; Stein, CM. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008, 196, 756-763 pp.]Search in Google Scholar
[4. Crowson, CS; Myasoedova, E; Davis, JM; Matteson, EL; Roger, VL; Therneau, TM; Fitz-Gibbon, P; Rodeheffer, RJ; Gabriel, SE. Increased Prevalence of Metabolic Syndrome Associated with Rheumatoid Arthritis in Patients without Clinical Cardiovascular Disease. J Rheumatol. 2011, 38(1), 29-35 pp.10.3899/jrheum.100346301440320952464]Search in Google Scholar
[5. Karvounaris, SA; Sidiropoulos, PI; Papadakis, JA; Spanakis, EK; Bertsias, GK; Kritikos, HD; Ganotakis, ES; Boumpas, DT. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis. 2007, 66, 28-33 pp.]Search in Google Scholar
[6. Love, TH; Qureshi, AA; Wood Karlson, E; Gelfand, JM; Choi, HK. Prevalence of the Metabolic Syndrome in Psoriasis - Results From the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011, 147(4), 419-424 pp.10.1001/archdermatol.2010.370307537521173301]Search in Google Scholar
[7. Papadakis, JA; Sidiropoulos, PI; Karvounaris, SA; Vrentzos, GE; Spanakis, EK; Ganotakis, ES. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clinical and experimental rheumatology. 2009, 27(2), 292-298 pp.]Search in Google Scholar
[8. Sommer, D; Jenisch, S; Suchan, M; Christophers, E; Weichenthal, M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of Dermatological Research. 2007, 298, pp. 321-328.]Search in Google Scholar
[9. Raychaudhuri, SK; Chatterjee, S; Nguyen, C; Kaur, M; Jialal, I; Raychaudhuri, SP. Increased Prevalence of the Metabolic Syndrome in Patients with Psoriatic Arthritis. Metabolic Syndrome and Related Disorders. 2010, 8(4), pp. 331-334.]Search in Google Scholar
[10. Ridker, PM; Uring, JE; Cook, NR. C-reactive protein, the metabolic syndrome, and the risk of incident of cardiovascular events. Circulation. 2003, 107, 391 - 397 pp.]Search in Google Scholar
[11. Malesci, D; Niglio, A; Mennillo, GA; Buono, R; Valentini, G; La Montagna, G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol. 2007, 26, 710-714 pp.]Search in Google Scholar
[12. García-Gómez, C; Nolla, JM; Valverde, J; Narváez, J; Corbella, E; Pintó, X. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest. 2008, 38(9), 686-692 pp.10.1111/j.1365-2362.2008.01994.x18837746]Search in Google Scholar
[13. Boers, M; Nurmohamed, MT; Doelman, CJ; Lard, LR; Verhoeven, AC; Voskuyl, AE; Huizinga, TW; van de Stadt, RJ; Dijkmans, BA; van der Linden, S. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003, 62(9), pp. 842-845.]Search in Google Scholar
[14. Yudkin, JS; Stehouwer, CD; Emeis, JJ; Coppack, SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999, 19, 972 - 978 pp.]Search in Google Scholar
[15. Nevalainen, TJ; Haapamäki, MM; Grönroos, JM. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochimica et Biophysica Acta. 2000, 1488, pp. 83-90.]Search in Google Scholar
[16. Tietge, UJF; Maugeais, C; Lund-Katz, S; Grass, D; DeBeer, FC; Rader, FDJ. Human Secretory Phospholipase A2 Mediates Decreased Plasma Levels of HDL Cholesterol and ApoA-I in Response to Inflammation in Human ApoA-I Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002, 22, pp. 1213-1218.]Search in Google Scholar
[17. Toms, TE; Panoulas, VF; Holly, J; Douglas, KMJ; Kitas, GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 - more than just an antiinflammatory effect? A cross sectional study. Arthritis Research & Therapy. 2009, R110, 1-10 pp.]Search in Google Scholar
[18. Galajda, P; Mokáň, M; Prídavková, D; Tomášková, V; Šutarík, L; Kručinská, L; Bukovská, A; Rusnáková, G. Prevalencia metabolického syndrómu na Slovensku. Interná medicína. 2007, 6, 325-331 pp.]Search in Google Scholar
[19. Galajda, P. Prevalencia metabolického syndrómu na Slovensku. Kazuistiky v diabetologii. 2006, 2, 41-42 pp.]Search in Google Scholar